158 related articles for article (PubMed ID: 35403447)
1. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.
Capdevila J; Klochikhin A; Leboulleux S; Isaev P; Badiu C; Robinson B; Hughes BGM; Keam B; Parnis F; Elisei R; Gajate P; Gan HK; Kapiteijn E; Locati L; Mangeshkar M; Faoro L; Krajewska J; Jarzab B
Thyroid; 2022 May; 32(5):515-524. PubMed ID: 35403447
[No Abstract] [Full Text] [Related]
2. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
3. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib in progressive medullary thyroid cancer.
Elisei R; Schlumberger MJ; Müller SP; Schöffski P; Brose MS; Shah MH; Licitra L; Jarzab B; Medvedev V; Kreissl MC; Niederle B; Cohen EE; Wirth LJ; Ali H; Hessel C; Yaron Y; Ball D; Nelkin B; Sherman SI
J Clin Oncol; 2013 Oct; 31(29):3639-46. PubMed ID: 24002501
[TBL] [Abstract][Full Text] [Related]
5. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS; Robinson BG; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Sen S; Oliver JW; Banerjee K; Keam B; Capdevila J
Cancer; 2022 Dec; 128(24):4203-4212. PubMed ID: 36259380
[TBL] [Abstract][Full Text] [Related]
7. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
Schlumberger M; Elisei R; Müller S; Schöffski P; Brose M; Shah M; Licitra L; Krajewska J; Kreissl MC; Niederle B; Cohen EEW; Wirth L; Ali H; Clary DO; Yaron Y; Mangeshkar M; Ball D; Nelkin B; Sherman S
Ann Oncol; 2017 Nov; 28(11):2813-2819. PubMed ID: 29045520
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults.
Nguyen L; Benrimoh N; Xie Y; Offman E; Lacy S
Anticancer Drugs; 2016 Aug; 27(7):669-78. PubMed ID: 27139820
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS; Robinson B; Sherman SI; Krajewska J; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Hernando J; Faoro L; Banerjee K; Oliver JW; Keam B; Capdevila J
Lancet Oncol; 2021 Aug; 22(8):1126-1138. PubMed ID: 34237250
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
12. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
[TBL] [Abstract][Full Text] [Related]
13. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
14. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
15. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
Miles DR; Lacy SA; Wada DR; Milwee S; Yaron Y; Nguyen LT
Cancer Chemother Pharmacol; 2017 Aug; 80(2):295-306. PubMed ID: 28634649
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
Cabanillas ME; Brose MS; Holland J; Ferguson KC; Sherman SI
Thyroid; 2014 Oct; 24(10):1508-14. PubMed ID: 25102375
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib: a review of its use in patients with medullary thyroid cancer.
Hoy SM
Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
